An interventional study of Short term variation and Visual interpretation in Fetal Growth Retardation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 6 sites in Netherlands. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Fetal Growth Retardation with a site in Netherlands — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Netherlands.
Among the 11 studies in Fetal Growth Retardation with a site in Netherlands, this one is one of 2 that started in 2025, is one of 3 with no phase, and was the 9th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →7 of the 11 studies in Fetal Growth Retardation with a site in Netherlands are open now. Recruiting first, the newest first:
Maxima Medical Center · Sites in Netherlands
Ages 18+ · Women only · Healthy volunteers
Maxima Medical Center · Sites in Netherlands
Ages 16+ · Women only · Healthy volunteers
University Hospital, Ghent · Sites in Netherlands, Belgium
Ages 18–45 · Women only
Leiden University Medical Center · Sites in Netherlands, United States, Belgium and 3 more countries
Ages 18–50
Erasmus Medical Center · Sites in Netherlands
Ages 16+ · Women only · Healthy volunteers
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 99 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 138 across the 4 interventional studies, 275 across the 7 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 7 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 2 studies filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
2 of the studies in Fetal Growth Retardation with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06010238Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)STV Analysis Versus Visual Evaluation of Cardiotocography in FGR | 2027-01-01 |
| NCT05423665University Hospital, GhentSpeckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Fetal Growth Retardation with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This stepped wedge cluster randomized clinical trial investigates whether in pregnant women with severe, early-onset fetal growth restriction, the use of STV analysis in fetal monitoring improves the chances of perinatal survival, compared with visual evaluation of the cardiotocography.
Severe, early-onset fetal growth restriction (FGR, \<32 weeks gestation) is a condition in which the fetus does not reach its growth potential due to placental insufficiency[. This condition affects about 0.3% of pregnancies, accounting for an estimated 15,000 babies in Europe being born premature below 32 weeks gestation. The main clinical dilemma of FGR lies in the timing of birth, given the balance of risks of antenatal mortality and severe damage to organs and the aggravated neonatal effects of prematurity: death or survival with severe neurodevelopmental impairment. The mainstay of clinical management in these cases pivots around the anticipation of the risk of fetal demise from placental oxygenation failure. The monitoring variables that are currently available comprise assessment of the severity of metabolic insufficiency (fetal size and growth, Doppler ultrasound, serum biomarkers) and the early detection of progressive fetal hypoxia with cardiotocography (CTG). The common approach is to deliver the fetus when signs of advanced hypoxia appear on CTG. A delicate balance exists between having the fetus born (too) early and facing the risks of extreme prematurity combined with a very low birthweight; and between delivering the fetus (too) late when the fetus has the disadvantage of hypoxia at birth. The decision when to deliver the fetus, is made mostly based on the CTG. The inter- and intra-observer variability could be overcome by software analysis according to the original Dawes\&Redman algorithm. The software calculates the short-term variation (STV) of the inter-beat interval expressed in milliseconds, and a range of secondary calculations. In contrast with repeated decelerations, when fetal hypoxia is considered evident, the place of the software analysis of the fetal heart rate variability is less clear. Although the advantages of mathematized and uniform quantification of the fetal heart rate variability appear self-evident, there are no studies with sufficient power to detect an association of intervention based on STV at any threshold with the most important outcomes: fetal death and long-term infant outcome.
The purpose of this study is to assess the outcomes of monitoring the fetal condition with STV in computerized CTG compared to visual interpretation of the CTG in order to time delivery in pregnant women with severe, early-onset FGR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Monitoring by visual interpretation of cardiotocography
Device: Visual interpretation
Short term variation by computer software analysis
Device: Short term variation
Short term variation in computer software analysis
Visual interpretation of cardiotocography
Proportion of pregnancies resulting in perinatal death
Perinatal death is defined as antenatal death or neonatal/infant death before discharge from NICU
Time frame: Before discharge from neonatal intensive care unit (NICU), up to 1 year
Proportion of children with major neonatal morbidity
Major neonatal morbidity is a composite outcome defined as intraventricular hemorrhage grade 3 or more, periventricular leukomalacia grade 2 or more, moderate or severe bronchopulmonary dysplasia, necrotizing enterocolitis Bell stage 2 or more, or retinopathy of prematurity requiring therapy.
Time frame: Before discharge from NICU, up to 1 year
Proportion of children with neonatal morbidities
Individual neonatal morbidities of the abovementioned composite outcome and additionally persisting ductus arteriosus, persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome (RDS), period of invasive mechanical ventilation in days, medication need, hypoglycaemia, neonatal jaundice, sepsis and cardiovascular function.
Time frame: Before discharge from NICU, up to 1 year
Proportion of children with neurodevelopmental impairment
Neurodevelopmental impairment is defined as an abnormal test on Bayley III Dutch version (or version IV if available) (composite cognitive score \< 85, composite motor score \< 85), cerebral palsy, with a Gross Motor Function Classification System (GMFCS) grade \> 1, hearing loss needing hearing aids, or severe visual loss (legally certifiable as blind or partially sighted) assessed at two years of corrected age
Time frame: At two years of corrected age
Plan to share: No — There is no current plan, but data will be available upon collaboration request
Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.
Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 18 months is below that.
Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Jan 2025 → Jun 2025, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →